Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.

@article{Lee2012ModernPD,
  title={Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.},
  author={Jonathan A. Lee and Mark T Uhlik and Christopher M Moxham and Dirk Tomandl and Daniel J Sall},
  journal={Journal of medicinal chemistry},
  year={2012},
  volume={55 10},
  pages={4527-38}
}
Strategy Jonathan A. Lee,*,† Mark T. Uhlik,‡ Christopher M. Moxham, Dirk Tomandl, and Daniel J. Sall Departments of †Quantitative Biology, ‡Cancer-Angiogenesis, Discovery Informatics, and Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana ImClone Systems, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, New York ■ INTRODUCTION The pharmaceutical industry (Pharma) is currently facing unprecedented challenges. In… CONTINUE READING